🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05738083
Recruiting Observational

Multi-Center Registry Cohort Study on Prognostic Factors and Prediction Model Construction in Aneurysmal SAH

NCT05738083 · tracked via the Priya Life Science China tracker
Sponsor
Second Affiliated Hospital of Nanchang University
Phase
Observational
Started
2018-10-01
Last updated
2026-04-30

Condition(s) studied

Aneurysmal Subarachnoid Hemorrhage

Investigational drug(s) / intervention(s)

Machine Leaning Models

Machine Leaning Models: Area Under the Curve (ROC): Measures the overall performance of the model across all classification thresholds. A higher AUC value indicates better performance. Accuracy: The proportion of correctly predicted outcomes (both positive and negative) out of all predictions made. Precision (Positive Predictive Value, PPV): The proportion of correctly predicted positive outcomes out of all predicted positive outcomes. Sensitivity (True Positive Rate, TPR): The proportion of actual positive outcomes that are correctly identified by the model. Specificity (True Negative Rate, TNR): The proportion of actual negative outcomes that are correctly identified by the model.

Study summary

PROSAH-MPC, a collaborative research project among neurosurgical centers in China, focuses on aneurysmal subarachnoid hemorrhage (aSAH). Its aim is to identify prognostic factors and develop robust prediction models for complications, disability, and mortality in aSAH patients. By leveraging a large, multi-center, prospective cohort design, PROSAH-MPC aims to overcome limitations of past studies and provide a more comprehensive understanding of the disease.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: * Subarachnoid hemorrhage confirmed by computed tomography (CT); * Cerebral angiography (CTA) and digital subtraction angiography (DSA) examination confirming intracranial aneurysm rupture as the cause of the subarachnoid hemorrhage; * Blood routine, biochemical function, blood coagulation function, and craniocerebral CT performed within 24 hours of symptom onset; * Underwent aneurysm clipping by surgery or endovascular embolization within 72 hours after-onset. Exclusion Criteria: * Aneurysm rupture bleeding time exceeding 24 hours before hospital admission; * Incomplete image data or blood test information; * Long-term use of anticoagulant medications such as aspirin or warfarin; * Admitted to hospital with active infectious diseases; * long-term anticoagulant drugs such as aspirin, wave dimensions; * Presence of other intracranial vascular malformations.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
The Second Affiliated Hospital of Nanchang University Nanchang Jiangxi Recruiting

More Second Affiliated Hospital of Nanchang University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05738083 on ClinicalTrials.gov ↗ ← All trials in China